Abstract
Survival was examined from a Turkish liver transplant center of patients with HCC, to identify prognostic factors. Data from 215 patients who underwent predominantly live donor liver transplant for HCC at our institute over 12 years were included in the study and prospectively recorded. They were 152 patients within and 63 patients beyond Milan criteria. Patients beyond Milan criteria were divided into two groups according to presence or absence of tumor recurrence. Recurrence-associated factors were analyzed. These factors were then applied to the total cohort for survival analysis. We identified four factors, using multivariate analysis, that were significantly associated with tumor recurrence. These were maximum tumor diameter, degree of tumor differentiation, and serum AFP and GGT levels. A model that included all four of these factors was constructed, the ‘Malatya criteria.’ Using these Malatya criteria, we estimated DFS and cumulative survival, for patients within and beyond these criteria, and found statistically significant differences with improved survival in patients within Malatya criteria of 1, 5, and 10-year overall survival rates of 90.1%, 79.7%, and 72.8% respectively, which compared favorably with other extra-Milan extended criteria. Survival of our patients within the newly defined Malatya criteria compared favorably with other extra-Milan extended criteria and highlight the usefulness of serum AFP and GGT levels in decision-making.
Similar content being viewed by others
Data Availability
The raw data used to support the findings of this study are available from the corresponding author upon request.
Change history
08 July 2020
The original version of this article unfortunately contained a mistake in the author group section.
Abbreviations
- AFP:
-
Alpha fetoprotein
- ALKP:
-
Alkaline phosphatase
- BCLC:
-
Barcelona Clinic Liver Cancer extended criteria
- BMI:
-
Body mass index
- CHILD:
-
Child-Pugh score
- DFS:
-
Disease-free survival
- ETC:
-
Extended Toronto criteria
- GGT:
-
Gamma glutamyl transferase
- GRWR:
-
Graft to recipient weight ratio
- HC:
-
Hagzhou criteria
- HCC:
-
Hepatocellular cancer
- LT:
-
Liver transplantation
- LDLT:
-
Live donor liver transplantation
- MC:
-
Milan criteria
- MELD:
-
Model for End Stage Liver Disease score
- MRI:
-
Magnetic resonance imaging
- MSCT:
-
Multislice computed tomography
- MTD:
-
Maximal tumor diameter
- NLR:
-
Neutrophil-lymphocyte ratio
- OS:
-
Overall survival
- OR:
-
Odds ratio
- PET/CT:
-
Positron emission tomography/computerized tomography scan
- PLR:
-
Platelet-to-lymphocyte ratio
- ROC:
-
Receiver operating characteristics
- TTS:
-
Total tumor size
- UCSF:
-
University of California, San Francisco criteria
References
World cancer report. http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.
Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394–403.
Llovet JM, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-Valdecasas JC. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan criteria (Barcelona clinic liver cancer extended criteria). Liver Transplant. 2018;24:369–79.
Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, de Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, van Hoek B, Majno P, Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43.
Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, Cleary SP, Lilly L, Cattral MS, Marquez M, Selzner M, Renner E, Selzner N, McGilvray ID, Greig PD, Grant DR. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology. 2016;64(6):2077–88.
Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85(12):1726–32.
Isik B, Ince V, Karabulut K, Kayaalp C, Yilmaz S. Living donor liver transplantation for hepatocellular carcinoma. Transplant Proc. 2012;44(6):1713–6.
Kayaalp C, Ince V, Ersan V, Karakas S, Kahraman AS, Yilmaz S. Liver transplantation for hepatocellular carcinoma at Inonu University. J Gastrointest Cancer. 2017;48(3):268–71.
Toso C, Kneteman NM, James Shapiro AM, Bigam DL. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int. 2009;22(9):869–75.
Mazzaferro V, Battiston C, Sposito C. Pro (with caution): extended oncologic indications in liver transplantation. Liver Transpl. 2018;24(1):98–103.
Patel SS, Arrington AK, McKenzie S, et al. Milan criteria and UCSF criteria: a preliminary comparative study of liver transplantation outcomes in the United States. Int J Hepatol. 2012;2012:253517.
Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DSK, Lassman C, Tong MJ, Hiatt JR, Busuttil RW. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246(3):502–9.
Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, Kneteman NM. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology. 2015;62(1):158–65.
Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, Ko GY, Park KM, Ha TY, Song GW. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl. 2008;14(7):935–45.
Ito T, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, Ogawa K, Sakamoto S, Ogura Y, Egawa H, Tanaka K, Uemoto S. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl. 2007;13(12):1637–44.
Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl. 2013;19(12):1343–53.
Carr BI, Guerra V, Giannini EG, et al. An HCC aggressiveness index and blood GTP, bilirubin and platelet levels. J Integr Oncol. 2016;5:172. https://doi.org/10.4172/2329-6771.1000172.
Carr BI, Guerra V, Giannini EG, et al. A liver index and its relationship to indices of HCC aggressiveness. J Integr Oncol. 2016;5(4):178.
Akkiz H, Carr BI, Yalçın KK, et al. Characteristics of hepatocellular carcinoma aggressiveness factors in Turkish patients. Oncology. 2018;94(2):116–24.
Wang NY, Zhang D, Zhao W, Fang GX, Shi YL, Duan MH. Clinical applicaton of an enzyme-linked immunosorbent assay detecting hepatoma-spesific gamma-glutamyltransferase. Hepatol Res. 2009;39:979–87.
Yao DF, Dong ZZ, Yao M. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2007;6(3):241–7.
Xia J, Song P, Sun Z, Sawakami T, Jia M, Wang Z. Advances of diagnostic and mechanistic studies of γ-glutamyl transpeptidase in hepatocellular carcinoma. Drug Discov Ther. 2016;10(4):181–7.
Lee SD, Kim SH. Role of positron emission tomography/computed tomography in living donor liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2016;5(5):408–14.
Lai Q, Avolio AW, Graziadei I, et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl. 2013;19(10):1108–18.
Otto G, Herber S, Heise M, Lohse AW, Mönch C, Bittinger F, Hoppe-Lotichius M, Schuchmann M, Victor A, Pitton M. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006;12(8):1260–7.
Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20(8):945–51.
Acknowledgments
The authors declare that there is no funding used for the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original version of this article was revised: The original version of this article unfortunately contained a mistake in the author group section. The correct name of the second author is “Sami Akbulut”.
Rights and permissions
About this article
Cite this article
Ince, V., Akbulut, S., Otan, E. et al. Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded Criteria. J Gastrointest Canc 51, 998–1005 (2020). https://doi.org/10.1007/s12029-020-00424-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-020-00424-w